{"success":true,"data":{"pressRelease":{"id":"113190","rtpr_id":"nGNX8XYzLQ","ticker":"BRVE","exchange":"NASDAQ","all_tickers":["BRVE"],"title":"Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares","author":"Globe Newswire","published_at":"2026-08-07T20:05:00.252Z","article_body":"SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq:\nBRVE), a clinical-stage biopharmaceutical company developing next-generation\ntherapeutics for hypertrophic cardiomyopathy (HCM) and other serious\ncardiovascular diseases, today announced the closing of its upsized initial\npublic offering of an aggregate of 24,437,500 shares of its common stock at an\ninitial public offering price of $18.00 per share, including the full exercise\nby the underwriters of their option to purchase 3,187,500 additional shares.\nAll shares of common stock were offered by Braveheart Bio. The shares began\ntrading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol\n“BRVE”.\n\nThe gross proceeds from the initial public offering, including full exercise\nof the underwriters’ option to purchase additional shares, before deducting\nunderwriting discounts and commissions and offering expenses payable by\nBraveheart Bio, were $439.9 million.\n\nGoldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor acted as joint\nbook-running managers for the offering.\n\nRegistration statements relating to the shares being sold in the initial\npublic offering have been filed with the U.S. Securities and Exchange\nCommission (SEC) and became effective on August 5, 2026. The offering was made\nonly by means of a prospectus, forming part of the effective registration\nstatement relating to these shares. Copies of the final prospectus may be\nobtained from the SEC’s website at www.sec.gov and may also be obtained\nfrom: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West\nStreet, New York, NY 10282, by telephone at (866) 471-2526, or by email at\nprospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate\nProspectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at\n(877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD\nSecurities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island\nAvenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com;\nStifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery\nStreet, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720\nor by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co.,\nAttention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY\n10022, or by email at prospectus@cantor.com.\n\nThis press release does not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation, or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or jurisdiction.\n\nAbout Braveheart Bio\nBraveheart Bio is a clinical-stage biopharmaceutical company focused on\ndeveloping therapies for patients with hypertrophic cardiomyopathy (HCM) and\nother serious cardiovascular diseases. Braveheart Bio’s lead product\ncandidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin\ninhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM)\nand non-obstructive HCM (nHCM). Braveheart Bio’s goal is to improve the\ntreatment options for these patients by enhancing speed of onset, depth of\ngradient response, systolic safety, reversibility and reducing prescribing\ncomplexity.\n\nInvestor Relations Contact\nAlexander Sharif\nNew Street Investor Relations\nAlexander@NewStreetIR.com\n\nMedia Contact\nFGS Global\nBraveheart-bio@fgsglobal.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7d124852-a695-4916-a0bf-6ff3051c9a0c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8XYzLQ","title":"Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares","author":"Globe Newswire","ticker":"BRVE","created":"2026-08-07T20:05:00.252Z","tickers":["BRVE"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq:\nBRVE), a clinical-stage biopharmaceutical company developing next-generation\ntherapeutics for hypertrophic cardiomyopathy (HCM) and other serious\ncardiovascular diseases, today announced the closing of its upsized initial\npublic offering of an aggregate of 24,437,500 shares of its common stock at an\ninitial public offering price of $18.00 per share, including the full exercise\nby the underwriters of their option to purchase 3,187,500 additional shares.\nAll shares of common stock were offered by Braveheart Bio. The shares began\ntrading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol\n“BRVE”.\n\nThe gross proceeds from the initial public offering, including full exercise\nof the underwriters’ option to purchase additional shares, before deducting\nunderwriting discounts and commissions and offering expenses payable by\nBraveheart Bio, were $439.9 million.\n\nGoldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor acted as joint\nbook-running managers for the offering.\n\nRegistration statements relating to the shares being sold in the initial\npublic offering have been filed with the U.S. Securities and Exchange\nCommission (SEC) and became effective on August 5, 2026. The offering was made\nonly by means of a prospectus, forming part of the effective registration\nstatement relating to these shares. Copies of the final prospectus may be\nobtained from the SEC’s website at www.sec.gov and may also be obtained\nfrom: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West\nStreet, New York, NY 10282, by telephone at (866) 471-2526, or by email at\nprospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate\nProspectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at\n(877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD\nSecurities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island\nAvenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com;\nStifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery\nStreet, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720\nor by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co.,\nAttention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY\n10022, or by email at prospectus@cantor.com.\n\nThis press release does not constitute an offer to sell or a solicitation of\nan offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation, or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or jurisdiction.\n\nAbout Braveheart Bio\nBraveheart Bio is a clinical-stage biopharmaceutical company focused on\ndeveloping therapies for patients with hypertrophic cardiomyopathy (HCM) and\nother serious cardiovascular diseases. Braveheart Bio’s lead product\ncandidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin\ninhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM)\nand non-obstructive HCM (nHCM). Braveheart Bio’s goal is to improve the\ntreatment options for these patients by enhancing speed of onset, depth of\ngradient response, systolic safety, reversibility and reducing prescribing\ncomplexity.\n\nInvestor Relations Contact\nAlexander Sharif\nNew Street Investor Relations\nAlexander@NewStreetIR.com\n\nMedia Contact\nFGS Global\nBraveheart-bio@fgsglobal.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7d124852-a695-4916-a0bf-6ff3051c9a0c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-07T20:05:00.356815656Z","server_sent_at_ms":1786133100356},"received_at":"2026-08-07T20:05:00.458Z","source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341381/0/en/braveheart-bio-announces-closing-of-upsized-initial-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares.html"},"analysis":{"id":"102192","press_release_id":"113190","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Braveheart Bio closed its upsized initial public offering, selling 24,437,500 shares of common stock at $18.00 per share for gross proceeds of $439.9 million.\n\nThe offering included the full exercise of the underwriters' option to purchase an additional 3,187,500 shares, indicating strong investor demand. Shares began trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol BRVE.\n\nThe company is a clinical-stage biopharmaceutical firm focused on BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor for hypertrophic cardiomyopathy.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Braveheart Bio raises $440M in upsized IPO to fund hypertrophic cardiomyopathy pipeline."},"keyFigures":{"dealValueUsd":439900000,"offeringPrice":18,"sharesOffered":24437500,"customDimensions":{"greenshoe_shares":3187500}},"quotedText":"","namedEntities":{"people":[{"name":"Alexander Sharif","role":"Investor Relations Contact"}],"products":["BHB-1893"],"companies":[{"name":"Braveheart Bio, Inc.","ticker":"BRVE"},{"name":"Goldman Sachs & Co. LLC","relationship":"underwriter"},{"name":"Jefferies","relationship":"underwriter"},{"name":"TD Cowen","relationship":"underwriter"},{"name":"Stifel","relationship":"underwriter"},{"name":"Cantor Fitzgerald","relationship":"underwriter"},{"name":"New Street Investor Relations","relationship":"investor relations"},{"name":"FGS Global","relationship":"media contact"}],"dollarAmounts":[{"amount":"$439.9 million","context":"gross proceeds from the initial public offering"},{"amount":"$18.00","context":"initial public offering price per share"}]},"materialImpact":{"score":4,"reasoning":"Successfully closed an upsized IPO raising $439.9 million in gross proceeds, representing a significant capital injection for a clinical-stage biopharmaceutical company."},"tickerRelevance":{"others":[],"primary":"BRVE"},"globalImportance":30,"audienceRelevance":45,"eventTypeSecondary":["dilution"],"importanceComponents":{"dealSize":"$439.9M","eventGravity":"IPO_close","sectorWeight":"Biotech","upsized_offering":true}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":4,"narrative":"Braveheart Bio closed its upsized initial public offering, selling 24,437,500 shares of common stock at $18.00 per share for gross proceeds of $439.9 million.\n\nThe offering included the full exercise of the underwriters' option to purchase an additional 3,187,500 shares, indicating strong investor demand. Shares began trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol BRVE.\n\nThe company is a clinical-stage biopharmaceutical firm focused on BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor for hypertrophic cardiomyopathy.","key_figures":{"dealValueUsd":439900000,"offeringPrice":18,"sharesOffered":24437500,"customDimensions":{"greenshoe_shares":3187500}},"named_entities":{"people":[{"name":"Alexander Sharif","role":"Investor Relations Contact"}],"products":["BHB-1893"],"companies":[{"name":"Braveheart Bio, Inc.","ticker":"BRVE"},{"name":"Goldman Sachs & Co. LLC","relationship":"underwriter"},{"name":"Jefferies","relationship":"underwriter"},{"name":"TD Cowen","relationship":"underwriter"},{"name":"Stifel","relationship":"underwriter"},{"name":"Cantor Fitzgerald","relationship":"underwriter"},{"name":"New Street Investor Relations","relationship":"investor relations"},{"name":"FGS Global","relationship":"media contact"}],"dollarAmounts":[{"amount":"$439.9 million","context":"gross proceeds from the initial public offering"},{"amount":"$18.00","context":"initial public offering price per share"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-07T20:15:49.984Z","global_importance":30,"audience_relevance":45,"importance_components":{"dealSize":"$439.9M","eventGravity":"IPO_close","sectorWeight":"Biotech","upsized_offering":true}},"durationMs":152606,"modelName":"glm-4.7"}}